11th IAS Conference on HIV Science (IAS 2021)
1 August 2021. Related: Conference reports.
Conference reports
IAS 2021: lenacapavir studies show impressive results in naive, extensive drug resistance and potential as PrEP
1 August 2021. Related: Conference reports, Antiretrovirals.
IAS 2021: HIV pipeline drugs: CAB/RPV LA, fostemsavir, paediatric dolutegravir, lenacapavir, islatravir, MK-8507 and albuvirtide
1 August 2021. Related: Conference reports, Antiretrovirals.
IAS 2021: Proving efficacy of next generation PrEP: counterfactual controls in lenacapavir and islatravir studies
1 August 2021. Related: Conference reports, HIV prevention and transmission, Research studies.
IAS 2021: WHO report links HIV to 30% increased mortality from COVID-19: based on South African data
1 August 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
IAS 2021: New demands for better transgender heath care: No data no more
1 August 2021. Related: Conference reports, HIV prevention and transmission.
13th International Workshop on HIV Paediatrics 2021
1 August 2021. Related: Conference reports, Paediatric care.
Dolutegravir superior to standard-of-care in young children: results from the ODYSSEY trial
1 August 2021. Related: Conference reports, Paediatric care.
5th Joint BHIVA/BASHH Conference 2021
1 July 2021. Related: Conference reports.
Few vertical HIV transmissions in the UK but contributing factors remain associated with inequality
1 July 2021. Related: Conference reports, Pregnancy.
5th joint BHIVA/BASHH conference 2021
1 June 2021. Related: Conference reports.
Weight changes on ART and how to lose weight successfully
1 June 2021. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Nutrition.
Selected presentations at BHIVA: COVID-19, PrEP in the UK, community involvement and more…
1 June 2021. Related: Conference reports, COVID-19: transmission & prevention, COVID-19.
28th Conference on Retroviruses and Opportunistic Infections (CROI 2021) virtual
1 June 2021. Related: Conference reports.
No differences in outcomes among women with and without HIV with high-risk pregnancies and COVID-19
1 June 2021. Related: Conference reports, Pregnancy, COVID-19: pathogenesis, COVID-19.
Dolutegravir-based regimens safe and effective in pregnancy and postpartum
1 June 2021. Related: Conference reports, Pregnancy.
Dolutegravir superior to standard of care in children and adolescents: results from the ODYSSEY trial
1 June 2021. Related: Conference reports, Paediatric care.
Joint BHIVA/BASHH Spring Conference 2021
3 May 2021. Related: Conference reports.
BHIVA registry reports HIV is independently linked to worse presentation and outcomes from COVID-19
3 May 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
HIV is linked to higher mortality from COVID-19 compared to HIV negative: 60% of deaths were black ethnicity
3 May 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
Case-control study of HIV positive people hospitalised with COVID-19
3 May 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
28th Conference on Retroviruses on Opportunistic Infections (CROI 2021)
1 April 2021. Related: Conference reports.
CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP
1 April 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Pregnancy outcomes and weight gain with dolutegravir and TAF
1 April 2021. Related: Conference reports, Pregnancy.
CROI 2021: New compounds for prevention and treatment of COVID-19
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Oral molnupiravir at higher dose reduces SARS-CoV-2 viral load at day five in small phase 2 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Dual Eli-Lilly mAb bamlanivimab and etesevimab reduces hospitalisation after single infusion: results from BLAZE-1 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Dual Regeneron mAbs casirivimab with imdevimab reduce transmission: interim results from phase 3 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
CROI 2021: Presentations from the LEAP workshop 2021
1 April 2021. Related: Conference reports, Other news.
CROI 2021: Presentations on NATAP.org
1 April 2021. Related: Conference reports, Other news.
28th Conference on Retroviruses and Opportunistic Infections (CROI 2021)
12 March 2021. Related: Conference reports.
CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV
12 March 2021. Related: Conference reports, COVID-19: treatment access, COVID-19: investigational drugs, COVID-19.
CROI 2021: Community challenge 6-month CROI pay wall – rather than usual open access…
12 March 2021. Related: Conference reports, Other news.
CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance
12 March 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021
12 March 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Islatravir dosing for once-monthly and annual PrEP: if effective this could end HIV transmission
12 March 2021. Related: Conference reports, HIV prevention and transmission.
CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial
12 March 2021. Related: Conference reports, Treatment strategies.
CROI 2021: HIV capsid uncoats in the CD4 nucleus rather than the cytoplasm – viral lifecycle updated…
12 March 2021. Related: Conference reports, Virology.
CROI 2021: Community HIV cure workshops online
12 March 2021. Related: Conference reports, Cure-related research.
R4P virtual conference (2021)
24 February 2021. Related: Conference reports, HIV prevention and transmission.
VRC01 antibody only prevents minority of HIV infections: AMP study results
24 February 2021. Related: Conference reports, HIV prevention and transmission.
Long-acting bNAb is safe and well tolerated and achieves target concentrations in newborns (VRC07-523LS)
24 February 2021. Related: Conference reports, Paediatric care, HIV prevention and transmission.
Promising data for multipurpose technologies to prevent HIV and pregnancy
24 February 2021. Related: Conference reports, Pregnancy, HIV prevention and transmission.
12th International Workshop on HIV paediatrics
24 February 2021. Related: Conference reports.
New LPV/r-based fixed dose HIV combination for young children: first results with Quadrimune 4-in-1
24 February 2021. Related: Conference reports, Paediatric care.
BHIVA 2020 virtual conference now online
22 January 2021. Related: Conference reports.
U=U is supported by a single undetectable viral load in the context of good adherence
22 January 2021. Related: Conference reports, HIV prevention and transmission.
Selected plenary talks and workshops from BHIVA 2020
22 January 2021. Related: Conference reports, On the web.
BHIVA 2020 virtual conference
9 December 2020. Related: Conference reports.
Worryingly low HIV knowledge among health workers at London hospital: 80% unaware of U=U, 36% worried about their risk from patients
9 December 2020. Related: Conference reports, HIV prevention and transmission.
12th International Workshop on HIV paediatrics
9 December 2020. Related: Conference reports.
Dolutegravir dosing for infants and young children
9 December 2020. Related: Conference reports, Paediatric care.
HIV Therapy Glasgow 2020
11 November 2020. Related: Conference reports.
Adverse pregnancy outcomes among Spanish women hospitalised with COVID-19
11 November 2020. Related: Conference reports, Pregnancy, COVID-19: transmission & prevention, COVID-19.
51st World Conference on Lung Health
11 November 2020. Related: Conference reports.
No increase in adverse birth outcomes with IPT-exposure in pregnancy in two African cohorts
11 November 2020. Related: Conference reports, Pregnancy, TB coinfection.
International workshop on clinical pharmacology of HIV, hepatitis, and other antiviral drugs
11 November 2020. Related: Conference reports.
New neonatal liquid formulations of dolutegravir have comparable bioavailability to dispersible paediatric tablet
11 November 2020. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
HIV Therapy Glasgow 2020
15 October 2020. Related: Conference reports.
Capsid inhibitor lenacapavir, dosed six-monthly, has high barrier to drug resistance and no cross-resistance to other classes
14 October 2020. Related: Conference reports, Antiretrovirals.
Single doses of MK-8507 reduce viral load by mean –1.5 log and support once-weekly dosing above 80 mg
14 October 2020. Related: Conference reports, Antiretrovirals.
Weight gain with dolutegravir-based ART in Nigerian cohort
14 October 2020. Related: Conference reports, Side effects.
COVID-19: pathogenesis and treatment
14 October 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
EACS guidelines updated (v.10.1) for Glasgow conference
14 October 2020. Related: Conference reports, Guidelines.